AP118A - Prodrugs of antiflammatory 3-acyl-2-oxindole-1-carboxamides - Google Patents

Prodrugs of antiflammatory 3-acyl-2-oxindole-1-carboxamides Download PDF

Info

Publication number: AP118A
Authority: AP; ARIPO
Prior art keywords: compound; carbon atoms; calcd; recrystallization; yield
Prior art date: 1988-10-18

Application number

APAP/P/1989/000141A

Other languages

English (en)

Other versions

AP8900141A0 (en

Inventor

Thomas C Crawford

Lawrence Alan Reiter

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-18

Filing date

1989-10-16

Publication date

1991-02-22

1989-10-16 Application filed by Pfizer filed Critical Pfizer

1989-10-31 Publication of AP8900141A0 publication Critical patent/AP8900141A0/xx

1991-02-22 Application granted granted Critical

1991-02-22 Publication of AP118A publication Critical patent/AP118A/en

Links

229940002612 prodrug Drugs 0.000 title abstract description 12
239000000651 prodrug Substances 0.000 title abstract description 12
-1 methoxybenzyl Chemical group 0.000 claims abstract description 17
125000000217 alkyl group Chemical group 0.000 claims abstract description 15
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims abstract description 14
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
239000001257 hydrogen Substances 0.000 claims abstract description 14
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 14
125000001589 carboacyl group Chemical group 0.000 claims abstract description 13
125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 13
125000001153 fluoro group Chemical group F* 0.000 claims abstract description 9
125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 8
230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 6
125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract description 4
125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims abstract description 3
125000006678 phenoxycarbonyl group Chemical group 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 77
238000000034 method Methods 0.000 claims description 66
125000004432 carbon atom Chemical group C* 0.000 claims description 47
125000003545 alkoxy group Chemical group 0.000 claims description 8
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 4
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 4
206010061218 Inflammation Diseases 0.000 claims description 3
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 3
230000004054 inflammatory process Effects 0.000 claims description 3
125000002252 acyl group Chemical group 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
150000002148 esters Chemical class 0.000 abstract description 6
230000000202 analgesic effect Effects 0.000 abstract description 3
150000002084 enol ethers Chemical class 0.000 abstract description 2
239000003795 chemical substances by application Substances 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 120
238000001953 recrystallisation Methods 0.000 description 48
238000001819 mass spectrum Methods 0.000 description 47
238000005160 1H NMR spectroscopy Methods 0.000 description 35
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 17
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
238000005481 NMR spectroscopy Methods 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
239000000203 mixture Substances 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000000047 product Substances 0.000 description 6
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
238000001914 filtration Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical class O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000002260 anti-inflammatory agent Substances 0.000 description 4
229940121363 anti-inflammatory agent Drugs 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000002168 alkylating agent Substances 0.000 description 3
229940100198 alkylating agent Drugs 0.000 description 3
150000004649 carbonic acid derivatives Chemical class 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
206010053155 Epigastric discomfort Diseases 0.000 description 2
102000003820 Lipoxygenases Human genes 0.000 description 2
108090000128 Lipoxygenases Proteins 0.000 description 2
PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 2
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
235000009518 sodium iodide Nutrition 0.000 description 2
150000003871 sulfonates Chemical class 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010030124 Oedema peripheral Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000007810 chemical reaction solvent Substances 0.000 description 1
239000013058 crude material Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
239000012259 ether extract Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000000155 melt Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
RDOXTESZEPMUJZ-UHFFFAOYSA-N methyl phenyl ether Natural products COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
150000005623 oxindoles Chemical class 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical group 0.000 description 1
229910001961 silver nitrate Inorganic materials 0.000 description 1
239000002002 slurry Substances 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
210000002437 synoviocyte Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pain & Pain Management (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

APAP/P/1989/000141A 1988-10-18 1989-10-16 Prodrugs of antiflammatory 3-acyl-2-oxindole-1-carboxamides AP118A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US1988/003658 WO1990004393A1 (fr)	1988-10-18	1988-10-18	Promedicaments de 3-acyle-2-indoxyle-1-carboxamides anti-inflammatoires

Publications (2)

Publication Number	Publication Date
AP8900141A0 AP8900141A0 (en)	1989-10-31
AP118A true AP118A (en)	1991-02-22

Family

ID=22208957

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1989/000141A AP118A (en)	1988-10-18	1989-10-16	Prodrugs of antiflammatory 3-acyl-2-oxindole-1-carboxamides

Country Status (33)

Country	Link
US (1)	US5118703A (fr)
JP (1)	JPH07597B2 (fr)
KR (1)	KR910007237B1 (fr)
CN (1)	CN1022241C (fr)
AP (1)	AP118A (fr)
AR (1)	AR246519A1 (fr)
AT (1)	ATE125794T1 (fr)
AU (1)	AU606819B2 (fr)
BG (1)	BG50834A3 (fr)
CA (1)	CA1339558C (fr)
CZ (1)	CZ278983B6 (fr)
DD (1)	DD285604A5 (fr)
DK (1)	DK514989A (fr)
EG (1)	EG19887A (fr)
FI (1)	FI95253C (fr)
HU (1)	HU208421B (fr)
IE (1)	IE66586B1 (fr)
IL (1)	IL91960A (fr)
IS (1)	IS1598B (fr)
MA (1)	MA21657A1 (fr)
MX (1)	MX18021A (fr)
MY (1)	MY104238A (fr)
NO (1)	NO178027C (fr)
NZ (1)	NZ231044A (fr)
OA (1)	OA09140A (fr)
PH (1)	PH27554A (fr)
PL (2)	PL163112B1 (fr)
PT (1)	PT92000B (fr)
RO (1)	RO109195B1 (fr)
RU (1)	RU2036905C1 (fr)
SK (1)	SK278175B6 (fr)
WO (1)	WO1990004393A1 (fr)
YU (1)	YU48070B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5059693A (en) *	1989-10-06	1991-10-22	Pfizer Inc.	Process for making 3-aroyl-2-oxindole-1-carboxamides
ATE146181T1 (de) *	1992-11-23	1996-12-15	Pfizer	Regioselektive synthese von 4-chlor-2- thiophencarbonsäure
US5270331A (en) *	1993-01-26	1993-12-14	Pfizer, Inc.	Prodrugs of antiinflammatory 3-acyl-2-oxindole-1-carboxamides
WO1994018194A1 (fr) *	1993-02-09	1994-08-18	Pfizer Inc.	Oxindole 1-[n-(alcoxycarbonyl)] carboxamides et 1-(n-carboxamido)carboxamides utilises comme agents anti-inflammatoires.
US5449788A (en) *	1994-01-28	1995-09-12	Catalytica, Inc.	Process for preparing 2-oxindole-1-carboxamides
CN1094819C (zh) *	1997-04-30	2002-11-27	大兴株式会社	环状坯料之制造装置
EP0984012A3 (fr) *	1998-08-31	2001-01-10	Pfizer Products Inc.	Promedicaments d'oxindole liberant du monoxyde d'azote avec propriétés analgesiques et antiinflammatoires
MXPA02004010A (es) *	1999-10-26	2002-10-23	Univ Texas Southwestern Med Ct	Metodos para tratamiento de perdida capilar que consisten en administrar compuesto de indolina.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL96047C (fr) *	1956-06-08
US3564009A (en) *	1966-01-13	1971-02-16	Sumitomo Chemical Co	Process for producing 1-acylindole derivatives
BE756447A (fr) *	1969-10-15	1971-03-22	Pfizer	Oxindolecarboxamides
US3923996A (en) *	1972-07-31	1975-12-02	Sandoz Ag	3-Substituted-oxindoles in compositions and methods of treating obesity
IE53102B1 (en) *	1981-05-12	1988-06-22	Ici Plc	Pharmaceutical spiro-succinimide derivatives
DE3268971D1 (en) *	1981-10-06	1986-03-20	Ici Plc	Biochemical process
US4556672A (en) *	1984-03-19	1985-12-03	Pfizer Inc.	3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
US4752609A (en) *	1985-06-20	1988-06-21	Pfizer Inc.	Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
US5036099A (en) *	1987-02-02	1991-07-30	Pfizer Inc.	Anhydrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide
EP0365194B1 (fr) *	1988-10-18	1995-08-02	Pfizer Inc.	Prodrogues de 3-aryl-2-oxindole-1-carboxamide antiinflammatoires
US5047554A (en) *	1989-04-18	1991-09-10	Pfizer Inc.	3-substituted-2-oxindole derivatives
US5059693A (en) *	1989-10-06	1991-10-22	Pfizer Inc.	Process for making 3-aroyl-2-oxindole-1-carboxamides

1988
- 1988-10-18 HU HU886740A patent/HU208421B/hu not_active IP Right Cessation
- 1988-10-18 WO PCT/US1988/003658 patent/WO1990004393A1/fr not_active Ceased
- 1988-10-18 US US07/675,883 patent/US5118703A/en not_active Expired - Lifetime
- 1988-10-18 MX MX1802188A patent/MX18021A/es unknown
- 1988-10-18 SK SK5906-89A patent/SK278175B6/sk unknown
- 1988-10-18 RO RO147347A patent/RO109195B1/ro unknown
1989
- 1989-09-20 IS IS3509A patent/IS1598B/is unknown
- 1989-09-28 CA CA000614317A patent/CA1339558C/fr not_active Expired - Fee Related
- 1989-10-04 PH PH39329A patent/PH27554A/en unknown
- 1989-10-09 AT AT89310319T patent/ATE125794T1/de active
- 1989-10-12 IL IL9196089A patent/IL91960A/xx not_active IP Right Cessation
- 1989-10-16 MY MYPI89001415A patent/MY104238A/en unknown
- 1989-10-16 PT PT92000A patent/PT92000B/pt not_active IP Right Cessation
- 1989-10-16 AP APAP/P/1989/000141A patent/AP118A/en active
- 1989-10-16 BG BG090022A patent/BG50834A3/xx unknown
- 1989-10-16 YU YU200589A patent/YU48070B/sh unknown
- 1989-10-17 AR AR89315179A patent/AR246519A1/es active
- 1989-10-17 JP JP1270174A patent/JPH07597B2/ja not_active Expired - Lifetime
- 1989-10-17 AU AU42956/89A patent/AU606819B2/en not_active Ceased
- 1989-10-17 DD DD89333653A patent/DD285604A5/de not_active IP Right Cessation
- 1989-10-17 PL PL89296831A patent/PL163112B1/pl unknown
- 1989-10-17 MA MA21909A patent/MA21657A1/fr unknown
- 1989-10-17 PL PL89281871A patent/PL162316B1/pl unknown
- 1989-10-17 NZ NZ231044A patent/NZ231044A/en unknown
- 1989-10-17 CN CN89107943A patent/CN1022241C/zh not_active Expired - Fee Related
- 1989-10-17 KR KR1019890014914A patent/KR910007237B1/ko not_active Expired
- 1989-10-17 OA OA59665A patent/OA09140A/fr unknown
- 1989-10-17 DK DK514989A patent/DK514989A/da not_active Application Discontinuation
- 1989-10-17 IE IE333289A patent/IE66586B1/en not_active IP Right Cessation
- 1989-10-18 CZ CS895906A patent/CZ278983B6/cs not_active IP Right Cessation
- 1989-10-18 EG EG49689A patent/EG19887A/xx active
1991
- 1991-04-17 FI FI911855A patent/FI95253C/fi not_active IP Right Cessation
- 1991-04-17 NO NO911512A patent/NO178027C/no unknown
- 1991-04-17 RU SU914895525A patent/RU2036905C1/ru active

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chem. Ber. 109 (2) pp.723-739, (1976). *
Chemical Abstracts, Vol. 110, 1989, 18555r; *

Also Published As

Publication number	Publication date
IS1598B (is)	1996-05-20
AR246519A1 (es)	1994-08-31
HUT58052A (en)	1992-01-28
ATE125794T1 (de)	1995-08-15
SK590689A3 (en)	1996-03-06
IL91960A0 (en)	1990-07-12
FI95253C (fi)	1996-01-10
PT92000B (pt)	1995-06-30
NO911512D0 (no)	1991-04-17
PT92000A (pt)	1990-04-30
AP8900141A0 (en)	1989-10-31
NO911512L (no)	1991-06-12
WO1990004393A1 (fr)	1990-05-03
JPH07597B2 (ja)	1995-01-11
MY104238A (en)	1994-02-28
FI911855A0 (fi)	1991-04-17
CZ590689A3 (en)	1994-04-13
MA21657A1 (fr)	1990-07-01
RO109195B1 (ro)	1994-12-30
NZ231044A (en)	1990-12-21
NO178027B (no)	1995-10-02
EG19887A (en)	1996-03-31
US5118703A (en)	1992-06-02
YU200589A (en)	1991-02-28
HU208421B (en)	1993-10-28
CN1041938A (zh)	1990-05-09
DK514989D0 (da)	1989-10-17
IE66586B1 (en)	1996-01-24
RU2036905C1 (ru)	1995-06-09
OA09140A (fr)	1991-10-31
PL163112B1 (pl)	1994-02-28
HU886740D0 (en)	1991-07-29
IS3509A7 (is)	1990-04-19
IL91960A (en)	1994-04-12
FI95253B (fi)	1995-09-29
DK514989A (da)	1990-04-19
CN1022241C (zh)	1993-09-29
DD285604A5 (de)	1990-12-19
CZ278983B6 (en)	1994-11-16
BG50834A3 (en)	1992-11-16
NO178027C (no)	1996-01-10
YU48070B (sh)	1997-01-08
PH27554A (en)	1993-08-18
MX18021A (es)	1993-11-01
CA1339558C (fr)	1997-11-25
AU606819B2 (en)	1991-02-14
KR910007237B1 (ko)	1991-09-24
SK278175B6 (en)	1996-03-06
KR900006285A (ko)	1990-05-07
PL162316B1 (pl)	1993-09-30
IE893332L (en)	1990-04-18
JPH02149559A (ja)	1990-06-08
AU4295689A (en)	1990-04-26

Publication	Publication Date	Title
AU765427B2 (en)	2003-09-18	Inhibitors of phospholipase enzymes
Duflos et al.	2001	N-Pyridinyl-indole-3-(alkyl) carboxamides and derivatives as potential systemic and topical inflammation inhibitors
US4752613A (en)	1988-06-21	Sulphonamidothienylcarboxylic acid compounds
AP118A (en)	1991-02-22	Prodrugs of antiflammatory 3-acyl-2-oxindole-1-carboxamides
US5104891A (en)	1992-04-14	Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension
EP0540400A1 (fr)	1993-05-05	Dérivés de quinoléine, utile comme angiotensine II antagonistes
CA2364864C (fr)	2006-07-18	Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions phamaceutiques qui les contiennent
JP2006514613A (ja)	2006-05-11	Ｎ−ベンゾジオキソリル、ｎ−ベンゾジオキサニルおよびｎ−ベンゾジオキセピニルアリールカルボキサミド誘導体、ならびにそれらを含む医薬組成物
EP0365194B1 (fr)	1995-08-02	Prodrogues de 3-aryl-2-oxindole-1-carboxamide antiinflammatoires
CA2447184A1 (fr)	2002-11-21	Derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
CA2313302C (fr)	2004-06-15	Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HU193274B (en)	1987-09-28	Process for preparing phenthiazines
JPH0523259B2 (fr)	1993-04-02
US4243665A (en)	1981-01-06	2-Heterocyclylalkyl-6-methoxy-naphthalenes
JPH0629264B2 (ja)	1994-04-20	２‐アミノ‐５‐ヒドロキシ‐４‐ピリミドン
WO1998031689A1 (fr)	1998-07-23	Derives d'acides boroniques ou phosphoniques inhibiteurs d'angiogenese
JPH072782A (ja)	1995-01-06	キノロン誘導体、その製造法およびそれを有効成分とする薬剤
JPS6185375A (ja)	1986-04-30	２，３−ジヒドロベンゾ〔ｂ〕フラン誘導体およびその製造法
JPH02172958A (ja)	1990-07-04	４―アミノフェノール誘導体
KR19980078076A (ko)	1998-11-16	캐테콜 카르복실아미드 유도체 및 이의 제조 방법